Healthcare Professional Portal
Healthcare Professional Portal
Up to 12 CPD points.
Best Practice takes place at the NEC Birmingham on Wednesday 7 and Thursday 8 October 2026: a free, CPD-accredited two-day event for UK primary care professionals, co-located with Respiratory Professional Care exhibition and conference.
Since its launch in 2014, Best Practice Birmingham has established itself as the UK’s leading commercial and educational event for the general practice and primary healthcare sectors, bringing together 4,500+ attendees, 250+ exhibitors, and 150+ sessions of clinically accredited education delivered by an expansive faculty of expert speakers.
This two-day event provides a focused opportunity to update your CPD, hear the latest clinical guidance, and share perspectives with colleagues who face the same demands across access, workforce, governance, digital delivery and financial sustainability.
Idorsia features in the programme, with a sponsored symposium on 8th October:
Register today – it’s free for all eligible UK healthcare professionals!
Idorsia will have a promotional stand at the congress. If you’re interested to hear more about how QUVIVIQ (daridorexant) can support your practice, come and find us at the congress to find out more.
Click the button below to be redirected to the congress website to find out more:
One of our product specialists would be happy to answer your questions.
QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated June 2024. Accessed July 2024.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
You already have an account?
Register to get access to:
You are being redirected to our partner’s website pro.idorsia.uk.
The content of this website contains promotional information for UK healthcare professionals and is managed by Idorsia Pharmaceuticals UK Ltd.
UK-DA-01463 | Date of preparation: April 2026
Your resource is ready to download.
Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.
Download will open in a new window.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
UK-DA-00445 | Date of preparation: Februrary 2026
Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.
It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.
For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.
This information is intended for UK Healthcare Professionals only.
By entering this site you are confirming that you are a UK Healthcare Professional.
UK-DA-00217 | Date of preparation: February 2026
